Literature DB >> 2696899

Effects of opiates on brain development.

R P Hammer1, A A Ricalde, J V Seatriz.   

Abstract

Perinatal morphine administration affects neuronal growth in the developing animal. Neuronal packing density was reduced by morphine treatment in both primary somatosensory cortex and preoptic area of the hypothalamus. However, glial packing density was increased, but only in hypothalamus, which could reflect greater severity of opiate-induced neurotoxicity in hypothalamus. Cortical pyramidal neurons show morphine-induced reduction of basilar dendritic growth limited to late-developing terminal branches. This effect is completely reversed by concurrent naltrexone administration. This selective effect could be caused by morphine acting at opiate receptors to inhibit extrinsic determinants of dendritic growth (e.g., afferent supply). The ontogeny of opiate receptors is also affected by perinatal morphine administration in a regionally-dependent manner. Mureceptors are downregulated by morphine in hypothalamus, but not in cortex. Differential maturity of receptors in these regions could be a factor in such differential drug effects. Therefore, different critical periods for opiate action in different regions of the developing brain could exist.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2696899

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  25 in total

Review 1.  Selective vulnerability of cerebellar granule neuroblasts and their progeny to drugs with abuse liability.

Authors:  Kurt F Hauser; Valeriya K Khurdayan; Robin J Goody; Avindra Nath; Alois Saria; James R Pauly
Journal:  Cerebellum       Date:  2003       Impact factor: 3.847

2.  Extracellular matrix plasticity and GABAergic inhibition of prefrontal cortex pyramidal cells facilitates relapse to heroin seeking.

Authors:  Michel C Van den Oever; Bart R Lubbers; Natalia A Goriounova; Ka W Li; Roel C Van der Schors; Maarten Loos; Danai Riga; Joost Wiskerke; Rob Binnekade; M Stegeman; Anton N M Schoffelmeer; Huibert D Mansvelder; August B Smit; Taco J De Vries; Sabine Spijker
Journal:  Neuropsychopharmacology       Date:  2010-06-30       Impact factor: 7.853

3.  Glial growth is regulated by agonists selective for multiple opioid receptor types in vitro.

Authors:  A Stiene-Martin; K F Hauser
Journal:  J Neurosci Res       Date:  1991-08       Impact factor: 4.164

Review 4.  Prenatal substance abuse: short- and long-term effects on the exposed fetus.

Authors:  Marylou Behnke; Vincent C Smith
Journal:  Pediatrics       Date:  2013-02-25       Impact factor: 7.124

5.  Sedation and analgesia in mechanically ventilated preterm neonates: continue standard of care or experiment?

Authors:  Christopher McPherson
Journal:  J Pediatr Pharmacol Ther       Date:  2012-10

6.  Adult responses to an ischemic stroke in a rat model of neonatal stress and morphine treatment.

Authors:  Sarah L Hays; Olga A Valieva; Ronald J McPherson; Sandra E Juul; Christine A Gleason
Journal:  Int J Dev Neurosci       Date:  2012-09-28       Impact factor: 2.457

Review 7.  Neonatal pain control and neurologic effects of anesthetics and sedatives in preterm infants.

Authors:  Christopher McPherson; Ruth E Grunau
Journal:  Clin Perinatol       Date:  2013-12-17       Impact factor: 3.430

Review 8.  Developmental anesthetic neurotoxicity: from animals to humans?

Authors:  Deshui Yu; Bin Liu
Journal:  J Anesth       Date:  2013-04-16       Impact factor: 2.078

9.  Outcome at 5-6 years of prematurely born children who received morphine as neonates.

Authors:  R MacGregor; D Evans; D Sugden; T Gaussen; M Levene
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1998-07       Impact factor: 5.747

10.  Brain Injury and Development in Preterm Infants Exposed to Fentanyl.

Authors:  Christopher McPherson; Matthew Haslam; Roberta Pineda; Cynthia Rogers; Jeffrey J Neil; Terrie E Inder
Journal:  Ann Pharmacother       Date:  2015-09-14       Impact factor: 3.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.